217 related articles for article (PubMed ID: 1662547)
1. Structure-activity relationships for platelet-activating factor (PAF) and analogues reveal differences between PAF receptors on platelets and macrophages.
Stewart AG; Grigoriadis G
J Lipid Mediat; 1991 Nov; 4(3):299-308. PubMed ID: 1662547
[TBL] [Abstract][Full Text] [Related]
2. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.
Grigoriadis G; Stewart AG
Br J Pharmacol; 1991 Sep; 104(1):171-7. PubMed ID: 1664761
[TBL] [Abstract][Full Text] [Related]
3. Differences in platelet-activating factor receptor mediated Ca++ response between hamster and guinea pig alveolar macrophages.
Chen J; Giri SN
J Pharmacol Exp Ther; 1997 Jun; 281(3):1047-58. PubMed ID: 9190835
[TBL] [Abstract][Full Text] [Related]
4. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. I. Studies on blood platelets in vitro.
Ostermann G; Hofmann B; Kertscher HP; Till U
J Lipid Mediat; 1990; 2(1):21-31. PubMed ID: 1966804
[TBL] [Abstract][Full Text] [Related]
5. PAF receptor. 2. Quantitative hydrophobic contribution of the agonist's etheroxid chain.
Heymans F; Steiner E; Jouquey S; Godfroid JJ
J Lipid Mediat; 1989; 1(5):303-12. PubMed ID: 2562436
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
Ring PC; Seldon PM; Barnes PJ; Giembycz MA
Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
[TBL] [Abstract][Full Text] [Related]
7. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
Tahraoui L; Floch A; Mondot S; Cavero I
Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
[TBL] [Abstract][Full Text] [Related]
8. Platelet-activating factor stimulation of tyrosine kinase and its relationship to phospholipase C in rabbit platelets: studies with genistein and monoclonal antibody to phosphotyrosine.
Dhar A; Paul AK; Shukla SD
Mol Pharmacol; 1990 Apr; 37(4):519-25. PubMed ID: 1691437
[TBL] [Abstract][Full Text] [Related]
9. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages.
Stewart AG; Dusting GJ
Br J Pharmacol; 1988 Aug; 94(4):1225-33. PubMed ID: 2850058
[TBL] [Abstract][Full Text] [Related]
10. Equine peritoneal macrophage production of thromboxane and prostacyclin in response to platelet activating factor and its receptor antagonist SRI 63-441.
Morris DD; Moore JN
Circ Shock; 1989 Jun; 28(2):149-58. PubMed ID: 2544315
[TBL] [Abstract][Full Text] [Related]
11. Desensitization of platelet-activating factor-stimulated protein phosphorylation in platelets.
Shukla SD; Morrison WJ; Dhar A
Mol Pharmacol; 1989 Apr; 35(4):409-13. PubMed ID: 2539556
[TBL] [Abstract][Full Text] [Related]
12. CV 6209 is a non-competitive antagonist of platelet-activating factor receptors on guinea-pig resident peritoneal macrophages.
Stewart AG
Clin Exp Pharmacol Physiol; 1989 Nov; 16(11):813-20. PubMed ID: 2558827
[TBL] [Abstract][Full Text] [Related]
13. [Effect of analogs and antagonists of the thrombocyte-activating factor (PAF) on blood platelet aggregation].
Lakin KM; Kulikov VI; Manevich EM; Muliar AG; Shvets VI
Farmakol Toksikol; 1988; 51(4):113-23. PubMed ID: 2847936
[No Abstract] [Full Text] [Related]
14. Activation of guinea pig peritoneal macrophages by platelet activating factor (PAF) and its agonists.
Hayashi H; Kudo I; Inoue K; Onozaki K; Tsushima S; Nomura H; Nojima S
J Biochem; 1985 Jun; 97(6):1737-45. PubMed ID: 2993272
[TBL] [Abstract][Full Text] [Related]
15. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
16. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.
Tahraoui L; Floch A; Cavero I
J Pharmacol Exp Ther; 1990 Mar; 252(3):1221-7. PubMed ID: 2156995
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
[TBL] [Abstract][Full Text] [Related]
18. Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms.
Hwang SB
J Lipid Mediat; 1990; 2(3-4):123-58. PubMed ID: 1966805
[TBL] [Abstract][Full Text] [Related]
19. Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
Curtin ML; Davidsen SK; Heyman HR; Garland RB; Sheppard GS; Florjancic AS; Xu L; Carrera GM; Steinman DH; Trautmann JA; Albert DH; Magoc TJ; Tapang P; Rhein DA; Conway RG; Luo G; Denissen JF; Marsh KC; Morgan DW; Summers JB
J Med Chem; 1998 Jan; 41(1):74-95. PubMed ID: 9438024
[TBL] [Abstract][Full Text] [Related]
20. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
